Technology | June 13, 2011

Multi-Tracer Platform Expands Cassette-Based Tracer Production to FDG Citrate Formulation

June 13, 2011 - Expanding upon its radiopharmacy platform, GE Healthcare is introducing new tracers to the FASTlab multi-tracer platform, an advanced positron emission tomography (PET) chemistry system on which the company is also developing PET proprietary agents. The system offers a number of significant enhancements to address the ever-evolving challenges of tracer production. With the addition of three new cassettes, users can access and produce FDG phosphate formulation, NaF, FMISO (HPLC free), FLT (HPLC free) and FDG citrate formulation (equivalent to Tracerlab MX standard formulation) on the same platform.

To facilitate regulatory preparation work, DMF type V, describing the platform, and DMF type II, outlining tracer cassette and synthesis, have been filed with the FDA.

FASTlab is an open-ended platform capable of accommodating new tracers as they are developed, eliminating the need to buy a dedicated synthesis module to process a different tracer. The innovative hardware and user-interface allows for consecutive production of different tracers on the same module. Clinicians just need to swap the cassette and the system is ready for the next tracer. Cassettes are barcoded — when loaded into the system, the processor reads the barcode and automatically downloads the right production parameters and batch information, helping customers achieve CFR 212 cGMP compliance. FASTlab is also a key component of Tracercenter, one source and one complete solution for enabling compliant PET tracer production.

For more information: www.gehealthcare.com

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.